Items in cart [1] Questions? Call 888-624-8373

Rights & Permissions Free Resources Display this book on your site! Related Titles Ensuring an Infectious Disease Workforce: Education and Training Needs for the 21st Century - Workshop Summary Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: The State of the Science, Evaluation, Implementation, and Economics Workshop Summary Other Related Titles Government and Industry Collaboration in AIDS Drug Development (1994) Institute of Medicine (IOM) Web Search Builder Use this book's key terms to search within this book, across our collection, or across the Web. Skim This Chapter Skim this chapter and use this chapter's key terms to search within this book. Reference Finder Paste in your own text to find books that relate to your topic. Page 18   E-mail  Facebook  Digg  Stumble  Twitter More The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy. Appendix Workshop Program Collaboration Between Government and Industry: Challenges and Opportunities for HIV Drug and Vaccine Development May 6, 1994 9:00 Welcome and Introduction Paul Volberding, Chief, AIDS Program and Clinical Oncology, San Francisco General Hospital, and Roundtable Cochair 9:15 Importance and Value of Government-Industry Collaboration on HIV Drug and Vaccine Development Patrick Gage, Chief Operating Officer, Genetics Institute, Inc. 9:30 Historical Perspectives on Government Technology Transfer Policy and the Pharmaceutical Industry Discussion Leader: Peter Barton Hutt, Partner, Covington & Burling Understanding the Legislative History of Intellectual Property Rights Involving the Pharmaceutical Industry Peter Barton Hutt, Partner, Covington & Burling Understanding the History of Fair Pricing Clauses and Their Implementation in Government Licensing of Intellectual Property Thomas Mays, Director, Office of Technology Development, National Cancer Institute 10:00 Discussion 10:30 Break Page 18 FRONT MATTER (R1-R10) CONTENTS (R11-R11) INTRODUCTION (1-2) HISTORICAL PERSPECTIVES ON GOVERNMENT TECHNOLOGY TRANSFER POLICY AND THE PHARMACEUTICAL INDUSTRY (3-6) IMPEDIMENTS TO COLLABORATION IN HIV DRUG DEVELOPMENT (7-11) OVERCOMING OBSTACLES TO COLLABORATION AND PROMOTING HIV DRUG DEVELOPMENT (12-16) CONCLUSION (17-17) APPENDIX (18-20)

Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.

OCR for page 18
Government and Industry Collaboration in AIDS Drug Development: Summary of a Workshop Held on May 6, 1994 Appendix Workshop Program Collaboration Between Government and Industry: Challenges and Opportunities for HIV Drug and Vaccine Development May 6, 1994 9:00 Welcome and Introduction Paul Volberding, Chief, AIDS Program and Clinical Oncology, San Francisco General Hospital, and Roundtable Cochair 9:15 Importance and Value of Government-Industry Collaboration on HIV Drug and Vaccine Development Patrick Gage, Chief Operating Officer, Genetics Institute, Inc. 9:30 Historical Perspectives on Government Technology Transfer Policy and the Pharmaceutical Industry Discussion Leader: Peter Barton Hutt, Partner, Covington & Burling Understanding the Legislative History of Intellectual Property Rights Involving the Pharmaceutical Industry Peter Barton Hutt, Partner, Covington & Burling Understanding the History of Fair Pricing Clauses and Their Implementation in Government Licensing of Intellectual Property Thomas Mays, Director, Office of Technology Development, National Cancer Institute 10:00 Discussion 10:30 Break

OCR for page 19
Government and Industry Collaboration in AIDS Drug Development: Summary of a Workshop Held on May 6, 1994 10:45 Impediments to Collaboration on HIV Drug and Vaccine Development: Defining the Issues Discussion Leader: Patrick Gage, Chief Operating Officer, Genetics Institute, Inc. Commentary from a Government/NIH Perspective Bruce Chabner, Director, Division of Cancer Treatment, National Cancer Institute A View from the Pharmaceutical Industry Stephen Carter, Senior Vice President, World Wide Clinical Research & Development, Bristol-Myers Squibb Pharmaceutical Research Institute Practical Implications of Rules Governing Intellectual Property Developed from Collaborative Relationships Harold Edgar, Professor of Law, Columbia University School of Law 11:30 Discussion 1:00 Lunch 2:00 Overcoming Obstacles to Collaboration and Promoting HIV Drug and Vaccine Development: Proposals for Resolution Discussion Leader: Martin Delaney, Founding Director, Project Inform Industry Perspective David Barry, Group Director, Research, Development and Medical Affairs, The Wellcome Research Laboratories Government/NIH Perspective Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases Congressional/Legislative Response Timothy Westmoreland, Counsel, Subcommittee on Health and the Environment, U.S. House of Representatives

OCR for page 20
Government and Industry Collaboration in AIDS Drug Development: Summary of a Workshop Held on May 6, 1994   David Schulke, Chief Health Policy Advisor, The Honorable Ron Wyden, U.S. House of Representatives, Member, Energy and Commerce Committee, Health and Environment Subcommittee 2:40 Discussion 4:15 Consideration of Future Directions: Summary of Salient Issues Daniel Hoth, Senior Vice President and Chief Medical Officer, Cell Genesys 4:45 Closing Remarks Barton Haynes, F.M. Hanes Professor of Medicine; Director, Duke University Arthritis Center; and Roundtable Cochair 5:00 Adjourn

Representative terms from entire chapter:

barton hutt